Richard Nolan Townsend sold $20k of LXEO
Chief Executive Officer at Lexeo Therapeutics, Inc.. 2,500 shares at an average of $7.82, traded Nov 11, 2024, filed Nov 13, 2024.
Score components
- +25RoleCEO
- 0Trade size$20k at market
- 0Share of holdings soldSold 2.0% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.9%, 3m -48.3%, 6m -64.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-026737, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | MOption exercise Common Stock10b5-1 | +2,500 | $2.33 | $5,825 | 123,195 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Common Stock10b5-1 | -2,500 | $7.82 | $20k | 120,695 | Nov 13, 2024 |
| Nov 11, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -2,500 | $0.00 | $0 | 121,155 | Nov 13, 2024 |
Related signals
Other insiders at Lexeo Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 41Moderate | Lexeo Therapeutics, Inc. | Richard Nolan Townsend Chief Executive Officer | $65k 10,173 shares | -3% | |
| 28Weak | Lexeo Therapeutics, Inc. | Jose Manuel Otero Chief Operating Officer | $19k 3,016 shares | -2% | |
| 30Weak | Lexeo Therapeutics, Inc. | Eric Adler Chief Medical Officer | $5,701 615 shares | -1% | |
| 30Weak | Lexeo Therapeutics, Inc. | Jenny Robertson Chief Legal Officer | $5,089 549 shares | -1% | |
| 40Moderate | Lexeo Therapeutics, Inc. | Richard Nolan Townsend Chief Executive Officer | $10k 1,127 shares | -0% | |
| 30Weak | Lexeo Therapeutics, Inc. | Tai Sandi See Chief Development Officer | $3,578 386 shares | -1% | |
| 30Weak | Lexeo Therapeutics, Inc. | Jose Manuel Otero Chief Technical Officer | $6,684 721 shares | -1% | |
| 35Weak | Lexeo Therapeutics, Inc. | Eric Adler Chief Medical Officer | $30k 3,382 shares | -4% | |
| 35Weak | Lexeo Therapeutics, Inc. | Jenny Robertson Chief Legal Officer | $32k 3,526 shares | -5% | |
| 50Moderate | Lexeo Therapeutics, Inc. | Richard Nolan Townsend Chief Executive Officer | $117k 13,133 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.